Lenalidomide Fresenius Kabi

Lenalidomide, the active ingredient in Lenalidomide Fresenius Kabi, is an immunomodulatory agent presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across regions.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cell proliferation. - Multiple Myeloma (initial therapy): Reduces tumor burden and extends progression‑free survival. - Multiple Myeloma (maintenance after transplant): Helps sustain remission and prolong overall survival. - Myelodysplastic Syndromes with del(5q): Improves blood counts and reduces transfusion dependence.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: Decreased neutrophil count, increasing infection risk. - Fatigue: Persistent tiredness affecting daily activities. - Nausea: Stomach upset often accompanied by vomiting.

Serious or Rare Side Effects: - Venous thromboembolism: Blood clots in deep veins or lungs, potentially life‑threatening. - Severe neutropenia: Marked drop in neutrophils leading to serious infections. - Secondary primary malignancies: Development of new cancers unrelated to the original disease.

Before initiating lenalidomide therapy, clinicians should consider several safety precautions. - Monitor blood counts: Perform regular complete blood count tests to detect cytopenias. - Assess renal function: Adjust dosing in patients with impaired kidney function. - Evaluate pregnancy risk: Avoid use in pregnant women and ensure effective contraception. - Avoid concomitant thalidomide: Combined use increases risk of severe peripheral neuropathy and thrombosis. - Counsel on infection signs: Educate patients to report fever or unexplained infections promptly. - Store at ambient temperature: Keep tablets in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin): May reduce therapeutic levels. - Anticoagulants (e.g., warfarin): Heightened risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - CYP3A4 substrate drugs (e.g., midazolam): May require dose adjustment. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Increased bleeding risk. - Live vaccines: Potentially reduced vaccine efficacy and safety concerns.